Imatinib Pharmacenter

Imatinib, the active ingredient in Imatinib Pharmacenter, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets malignant cells in chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor patients.

GNH USA supplies Imatinib Pharmacenter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery and support for oncology treatment programs globally.

Imatinib acts on malignant cells driven by specific tyrosine kinases and is indicated for the following conditions:

Chronic myeloid leukemia (CML): provides durable hematologic and cytogenetic responses, improving survival. Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): delivers targeted BCR‑ABL inhibition to achieve remission. Gastrointestinal stromal tumor (GIST): blocks KIT‑driven tumor growth, leading to disease control.

Adverse reactions reported with Imatinib vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that may improve over time. - Edema: swelling of the hands, feet or ankles due to fluid retention. - Muscle cramps: painful involuntary contractions, often in the lower limbs. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Severe neutropenia or leukopenia: marked reduction in white blood cells increasing infection risk. - Hepatotoxicity: significant elevation of liver enzymes that may indicate liver injury. - Cardiac failure or pulmonary hypertension: rare but potentially life‑threatening heart or lung vascular complications.

When prescribing Imatinib, clinicians should observe the following precautions to ensure patient safety.

- Monitor blood counts: perform regular complete blood count tests to detect cytopenias. - Assess liver function: check hepatic enzymes before initiation and periodically during therapy. - Evaluate cardiac status: screen for pre‑existing heart disease and monitor for signs of heart failure. - Avoid use in pregnancy unless benefits outweigh risks: discuss potential fetal effects with the patient. - Store at room temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Imatinib may interact with other medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase imatinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce drug levels and effectiveness. - Antacids containing aluminum or magnesium: may decrease oral absorption of imatinib.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Diuretics (e.g., furosemide): can exacerbate fluid retention. - QT‑prolonging agents: may increase risk of cardiac arrhythmias.